Hypothalamic–pituitary–adrenal axis perturbations in patients with fibromyalgia

Arthritis & Rheumatism

Volumn 37, Issue 11, 1994, Pages 1583-1592

  Crofford, Leslie J ^a,b   Pillemer, Stanley R ^b   Kalogeras, Konstantine T ^b   Cash, Joseph M ^b   Michelson, David ^c   Kling, Mitchel A ^e   Sternberg, Esther M ^e   Gold, Philip W ^e   Chrousos, George P ^d   Wilder, Ronald L ^e  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE; NEUROPEPTIDE Y;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROMYALGIA; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PRIORITY JOURNAL; STANDING; SUPINE POSITION;

ADULT; ARGININE; ARGIPRESSIN; CORTICOTROPIN; CORTICOTROPIN-RELEASING HORMONE; FEMALE; FIBROMYALGIA; HUMAN; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MIDDLE AGE; NEUROPEPTIDE Y; PITUITARY-ADRENAL SYSTEM;

EID: 0028099256     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780371105     Document Type: Article

References (51)

1. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee.
2. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls.
3. Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome.
4. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice.
5. Chronic fatigue syndrome research: definition and medical outcome assessment.
6. Fibrositis and psychological disturbance.
7. Psychological factors associated with primary fibromyalgia syndrome.
8. Psychological stress and the fibrositis/fibromyalgia syndrome.
9. The concepts of stress and stress system disorders: overview of physical and behavioral homeostasis.
10. Hypoimmune fatigue syndromes: diseases of the stress response
11. Corticotropin‐releasing hormone and pituitary‐adrenocortical responses in chronically stressed rats.
12. Evidence for a specific role of vasopressin in sustaining pituitary‐adrenocortical stress response in the rat.
13. Repeated stress‐induced activation of corticotropin‐releasing factor neurons enhances vasopressin stores and colocalization with corticotropin‐releasing factor in the median eminence of rats.
14. Neuropeptide Y and sympathetic neurotransmission.
15. Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis.
16. Neuroendocrinologic findings in primary fibromyalgia (soft tissue chronic pain syndrome) and in other chronic rheumatic conditions (rheumatoid arthritis, low back pain) (editorial).
17. Altered reactivity of the hypothalamic‐pituitary‐adrenal axis in the primary fibromyalgia syndrome.
18. Plasma tryptophan and musculoskeletal pain in non‐articular rheumatism (“fibrositis syndrome”).
19. Rheumatic pain modulation syndromes: the interrelationships between sleep, central nervous system, serotonin and pain.
20. Serotonin mediation of circadian periodicity of plasma 17‐hydroxycorticosteroids.
21. Relation of brain 5‐hydroxytryptamine content to the diurnal variation of plasma corticosterone in the rat.
22. A role for serotonin in the hypothalamic‐pituitary‐adrenal response to insulin stress.
23. Clinical characteristics of fibrositis. I. A “blinded,” controlled study of symptoms and tender points.
24. The corticotropin‐releasing hormone stimulation test: a possible aid in the evaluation of patients with adrenal insufficiency.
25. Evidence for impaired activation of the hypothalamic‐pituitary‐adrenal axis in patients with chronic fatigue syndrome.
26. Spontaneous and glucocorticoid‐inhibited adrenocorticotropic hormone and cortisol secretion are similar in healthy young and old men.
27. Corticotropin‐releasing factor stimulation of adrenocorticotropin and β‐endorphin release: effects of acute and chronic stress.
28. Increased plasma concentration, hypothalamic content, and in vitro release of arginine vasopressin in inflammatory disease‐prone, hypothalamic corticotropin‐releasing hormone‐deficient Lewis rats.
29. Suppression of hypothalamic‐pituitary‐adrenal axis responsiveness to stress in a rat model of acute cholestasis.
30. Chronic activation of the hypothalamo‐pituitary‐adrenal axis and loss of circadian rhythm during adjuvant‐induced arthritis in the rat.
31. Paradoxical responses of hypothalamic corticotropin‐releasing factor (CRF) messenger ribonucleic acid (mRNA) and CRF‐41 peptide and adenohypophysial proopiomelanacortin mRNA during chronic inflammatory stress.
32. Inflammatory mediator‐induced hypothalamic‐pituitary‐adrenal axis activation is defective in streptococcal cell wall arthritis susceptible Lewis rats.
33. A central nervous system defect in biosynthesis of corticotropin‐releasing hormone is associated with susceptibility to streptococcal cell wall arthritis in Lewis rats.
34. Corticotropin releasing hormone related behavioral and neuroendocrine responses to stress in Lewis and Fischer rats.
35. Neuropeptide Y and natural killer cell activity: findings in depression and Alzheimer caregiver stress.
36. Cerebrospinal fluid concentrations of neuropeptide Y in depressed patients and in controls.
37. Neuropeptide Y distribution in the rat brain.
38. Distribution of neuropeptide Y‐like immunoreactivity in the rat central nervous system. II. Immunohistochemical analysis.
39. Neuropeptide Y administration acutely increases hypothalamic corticotropin‐releasing factor immuno‐reactivity: lack of effect in other rat brain regions.
40. Regulation of the hypothalamo‐pituitary axis by neuropeptide Y.
41. Neurohormonal aspects of fibromyalgia syndrome.
42. 3H‐imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome
43. Double‐blind study of 5‐hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome.
44. Low levels of somatomedin C in patients with the fibromyalgia syndrome: a possible link between sleep and muscle pain.
45. Serum beta endorphin in primary fibromyalgia syndrome: a controlled study.
46. Cerebrospinal fluid levels of β‐endorphin in patients with fibromyalgia (fibrositis syndrome).
47. Intraventricular corticotropin‐releasing factor enhances behavioral effects of novelty.
48. Corticotropin‐releasing factor: actions on the sympathetic nervous system and metabolism.
49. Corticotropin‐releasing factor, grooming and ingestive behavior.